Fresenius SE & Co. (OTCMKTS:FSNUY) Stock Short Interest Report for October

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a large decrease in short interest in the month of October. As of October 30th, there was short interest totaling 53,811 shares, a decrease of 85.3% from the October 15th total of 367,297 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 166,740 shares, the short-interest ratio is presently 0.3 days.

Fresenius SE & Co. Stock Performance

Shares of OTCMKTS FSNUY opened at $14.99 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41. The business’s 50 day moving average is $13.02 and its two-hundred day moving average is $12.87. The company has a market cap of $33.77 billion, a P/E ratio of 14.71 and a beta of 0.63. Fresenius SE & Co. has a 12 month low of $10.33 and a 12 month high of $15.94.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.03. Fresenius SE & Co. had a return on equity of 10.24% and a net margin of 6.58%. The company had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.51 billion. On average, equities analysts expect that Fresenius SE & Co. will post 1.04 EPS for the current year.

Wall Street Analyst Weigh In

FSNUY has been the topic of a number of research analyst reports. Citigroup reiterated a “buy” rating on shares of Fresenius SE & Co. in a research note on Wednesday, October 28th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating. According to MarketBeat, Fresenius SE & Co. currently has an average rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co. KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain. Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912.